FOUNTAIN VALLEY, Calif., Feb. 22 /PRNewswire/ -- Sutura(R), Inc. ("Sutura"), a California-based medical device company, announced today that initial reaction to the new SuperStitch(R) product in Europe and the U.S. has been positive. The 'As Simple As 1-2-3 Concept', which Sutura believes makes it easier for physicians to deploy the SuperStitch, closes the femoral puncture site using the catheter sheath introducer to access the femoral artery wound.
In January, Sutura began accepting sales orders for the next generation SuperStitch in the United States as well as Europe. These orders follow a physician and clinician training program to assure proper and consistent use of the device, assuring reorders and satisfied customers.
"Since the introduction of the newly designed handle for the SuperStitch we have started receiving orders from medical facilities and Cath-Labs across Europe," said Anthony Nobles, CEO/President of Sutura. "In addition, we have successfully introduced the 6F SuperStitch to medical facilities in the United States and have received positive responses from U.S. physicians trying the SuperStitch for the first time."
"Our marketing program has moved to the next level with the first orders of the 'As Simple As 1-2-3 Concept' SuperStitch in the U.S.," said Tom Lindsey, Director of U.S. Sales and Marketing at Sutura(R). "The reception we are getting in Cath-Labs is positive and we believe that continued demonstration of the effectiveness of the SuperStitch will lead to additional sales."
Sutura, Inc. announced November 22, 2004 that it had signed an Agreement and Plan of Merger with Technology Visions Group, Inc. (BULLETIN BOARD: TVGR) of San Marcos, California. The merger is now proceeding through due diligence and satisfaction of closing conditions.
About Sutura, Inc.
Sutura, Inc. (http://www.suturaus.com/) is a medical device company that has developed a line of innovative, minimally invasive vessel closure devices to suture the puncture created in the femoral artery during catheter-based procedures, primarily in the fields of cardiology and radiology. The SuperStitch devices allow physicians to close the femoral puncture site using the catheter sheath introducer to access the femoral artery wound. Sutura believes that its products will allow a physician to more quickly and safely conclude catheter-based procedures and, in addition, allow the patient to become ambulatory sooner than with traditional methods of managing arterial puncture wounds. Sutura has received 510(k) clearance from the FDA to sell its F8 & F6 SuperStitch devices in the United States and has the CE Mark permitting sale in Europe. Sutura has also met all of the registration requirements for selling the SuperStitch devices in Australia. Sutura's headquarters are in Fountain Valley, California. "Sutura(R)" and "SuperStitch(R)" are registered trademarks of Sutura, Inc.
Forward-Looking Information Is Subject to Risk and Uncertainty
Certain statements in this press release may contain projections or "forward-looking" information (as defined in the Private Securities Litigation Reform Act of 1995) that involve risk and uncertainty. The words "aim," "plan," "likely," "believe," "expect," "anticipate," "intend," "estimate," "will," "should," "could," "may," and other expressions that indicate future events and trends identify forward-looking statements. These statements are not guaranties of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what we express or forecast in these forward-looking statements. As a result, these statements speak only as of the date they were made and we undertake no obligation to publicly update or revise any forward-looking statements. Our actual results and future trends may differ materially from our forward-looking statements depending on a variety of factors including the acceptance of the SuperStitch devices by medical providers and the marketplace in general and the success of the proposed marketing plan, the continued growth of the vessel closure marketplace and the company's ability to continue to expand and protect its technology patents.
Sutura, Inc.
In January, Sutura began accepting sales orders for the next generation SuperStitch in the United States as well as Europe. These orders follow a physician and clinician training program to assure proper and consistent use of the device, assuring reorders and satisfied customers.
"Since the introduction of the newly designed handle for the SuperStitch we have started receiving orders from medical facilities and Cath-Labs across Europe," said Anthony Nobles, CEO/President of Sutura. "In addition, we have successfully introduced the 6F SuperStitch to medical facilities in the United States and have received positive responses from U.S. physicians trying the SuperStitch for the first time."
"Our marketing program has moved to the next level with the first orders of the 'As Simple As 1-2-3 Concept' SuperStitch in the U.S.," said Tom Lindsey, Director of U.S. Sales and Marketing at Sutura(R). "The reception we are getting in Cath-Labs is positive and we believe that continued demonstration of the effectiveness of the SuperStitch will lead to additional sales."
Sutura, Inc. announced November 22, 2004 that it had signed an Agreement and Plan of Merger with Technology Visions Group, Inc. (BULLETIN BOARD: TVGR) of San Marcos, California. The merger is now proceeding through due diligence and satisfaction of closing conditions.
About Sutura, Inc.
Sutura, Inc. (http://www.suturaus.com/) is a medical device company that has developed a line of innovative, minimally invasive vessel closure devices to suture the puncture created in the femoral artery during catheter-based procedures, primarily in the fields of cardiology and radiology. The SuperStitch devices allow physicians to close the femoral puncture site using the catheter sheath introducer to access the femoral artery wound. Sutura believes that its products will allow a physician to more quickly and safely conclude catheter-based procedures and, in addition, allow the patient to become ambulatory sooner than with traditional methods of managing arterial puncture wounds. Sutura has received 510(k) clearance from the FDA to sell its F8 & F6 SuperStitch devices in the United States and has the CE Mark permitting sale in Europe. Sutura has also met all of the registration requirements for selling the SuperStitch devices in Australia. Sutura's headquarters are in Fountain Valley, California. "Sutura(R)" and "SuperStitch(R)" are registered trademarks of Sutura, Inc.
Forward-Looking Information Is Subject to Risk and Uncertainty
Certain statements in this press release may contain projections or "forward-looking" information (as defined in the Private Securities Litigation Reform Act of 1995) that involve risk and uncertainty. The words "aim," "plan," "likely," "believe," "expect," "anticipate," "intend," "estimate," "will," "should," "could," "may," and other expressions that indicate future events and trends identify forward-looking statements. These statements are not guaranties of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what we express or forecast in these forward-looking statements. As a result, these statements speak only as of the date they were made and we undertake no obligation to publicly update or revise any forward-looking statements. Our actual results and future trends may differ materially from our forward-looking statements depending on a variety of factors including the acceptance of the SuperStitch devices by medical providers and the marketplace in general and the success of the proposed marketing plan, the continued growth of the vessel closure marketplace and the company's ability to continue to expand and protect its technology patents.
Sutura, Inc.
© 2005 PR Newswire
